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Abstract 
Background: Arsenic is a common groundwater contaminant that has a 
variety of health impacts.  Currently, the drinking water standard 
established by the World Health Organization is 10 μg/L or ppb.  However, 
over 140 million people consume drinking water with arsenic levels that 
exceed the standard.  Arsenic is a known immunotoxin, and has been linked 
to increased morbidity and mortality from respiratory infections like the 
influenza virus.   
 
Objective: The goal of this study was to investigate the effects of in utero 
arsenic exposure on birth outcomes and influenza A virus (IAV) vaccine 
immunogenicity in the offspring.   
 
Methods: Female C57BL/6J mice were treated with either 0 or 100 ppb of 
arsenic through their drinking water.  After 1 to 2 weeks of exposure, females 
were mated with males.  Throughout pregnancy, females were continuously 
given treated water to model in utero exposure.  At 2 and 5 weeks of age, 
pups were immunized by intraperitoneal injection with an inactivated mouse-
adapted (ma) 2009 H1N1 IAV.  Vaccine immunogenicity was evaluated by 
enzyme-linked immunosorbent assays (ELISAs) and neutralizing antibody 
assays.  At 8 weeks of age, the pups were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
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H1N1 IAV.  Body weight and temperature of infected offspring were recorded 
daily, and tissue samples were collected throughout the IAV disease course.   
 
Results: In utero exposure caused a significant decrease in fetal weight at 
gestation day 17, as well as pup weight at 1 week of age.  Although pre-
challenge immunogenicity measurements including anti-ma2009 H1N1 IAV 
IgG titers and neutralizing antibody titers showed that in utero arsenic 
exposure does not adversely alter the antibody-mediated response initiated 
after vaccination, in utero exposure to arsenic did inhibit weight gain 
following challenge with the drift variant IAV.   
 
Conclusion: The results from this study confirm that arsenic is a 
developmental toxin.  Future research will be directed towards 
understanding how arsenic differentially targets the cellular and humoral 
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INVESTIGATING THE EFFECTS OF IN UTERO ARSENIC 
EXPOSURE ON BIRTH OUTCOMES AND INFLUENZA A VIRUS 
VACCINE IMMUNOGENICITY IN THE OFFSPRING 
 
PART 1: INTRODUCTION AND BACKGROUND 
 
1.1: Introduction 
 Arsenic is a naturally occurring element found in the earth’s crust, and 
therefore is a common contaminant of drinking water sources in many 
countries including Bangladesh, Chile, India, and the United States (World 
Health Organization 2018).  Individuals are most commonly exposed to 
arsenic through their drinking water; however, they can also be exposed to 
the metalloid by the ingestion of foods irrigated by contaminated water or 
through industrial processes such as mining (as reviewed by Ratnaike 2003).   
 The current standard for arsenic in drinking water established by the 
World Health Organization and the U.S. Environmental Protection Agency is 
10 μg/L (ppb).  However, more than 140 million individuals living in over 50 
different countries consume drinking water with arsenic levels that far 
exceed the standard (Figure 1; World Health Organization 2018; U.S. 
Environmental Protection Agency 2018).  For example, from 1958 to 1971, 
parts of Northern Chile experienced a period of prolonged exposure, with 
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arsenic levels 80 times greater than the drinking water standard (Steinmaus 
et al. 2013).   
 
 
Figure 1: Estimated risk of arsenic contamination in drinking water above 
the World Health Organization standard of 10 μg/L (Schwarzenbach et al. 
2010).   
 
 Having a better understanding of the health effects associated with 
arsenic is critical for protecting public health since millions of people are 
exposed to high levels of the metalloid in their drinking water.  Specifically, a 
greater emphasis needs to be placed on investigating how in utero exposure 
to arsenic can alter pregnancy outcomes, as well as immune system function 





1.2.1: Properties of Arsenic 
 Arsenic can be found in several forms.  When arsenic combines with 
carbon or hydrogen, it forms an organic arsenic compound.  When arsenic is 
bound to oxygen, chlorine, or sulfur, it forms an inorganic arsenic compound 
(Agency of Toxic Substances and Disease Registry 2011a).  Organic arsenic 
compounds are commonly found in seafood, while inorganic arsenic 
compounds are responsible for the contamination of groundwater sources 
(Schoof et al. 1999).  Previously, exposure to arsenic was linked to the use of 
arsenic-containing wood preservatives, as well as pesticides and paints.  
Since its elimination in these products, exposure to inorganic arsenic occurs 
primarily through the consumption of contaminated drinking water (Centers 
for Disease Control and Prevention 2009).  Individuals can also be exposed to 
inorganic arsenic through the inhalation of arsenic containing coal fumes and 
through the ingestion of poultry treated with arsenical growth promoters 
such as roxarsone and nitrasone (Agency for Toxic Substances and Disease 
Registry 2011a; U.S. Food and Drug Administration 2017).   
 In the environment, inorganic arsenic exists as arsenite (AsIII) or 
arsenate (AsV; Hughes 2002).  In the human body, arsenate is metabolized to 
arsenite, which is subsequently methylated to form monomethylarsonic acid 
(MMA) and dimethylarsinic acid (DMA), two organic arsenic compounds that 
are more readily excreted in comparison to their inorganic counterparts 
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(Drobna et al. 2009; Vahter and Concha 2001).  However, both MMA and 
DMA play important roles in arsenic toxicity because of their cytotoxic and 
genotoxic properties, as well as their action as a tumor promoter, enzyme 
inhibitor, and teratogen (as reviewed by Dangleben, Skibola, and Smith 2013; 
Drobna et al. 2009; Hegedus et al. 2008; Mass et al. 2001).   
 Acute exposure to arsenic can lead to health problems including 
nausea, abdominal pain, and diarrhea.  Numbness, muscle cramping, and 
death can also occur upon exposure to high doses of arsenic (as reviewed by 
Ratnaike 2003; George et al. 2014).  Chronic exposure is linked to cancer of 
the lungs, bladder, and liver, skin lesions, peripheral neuropathy, and 
anemia (as reviewed by Naujokas et al. 2013).  In addition, chronic exposure 
to arsenic is associated with developmental disorders, immune dysfunction, 
and adverse pregnancy outcomes (as reviewed by Attreed, Navas-Aciens, and 
Heaney 2017; Concha et al. 1998; Biswas et al. 2008).  Currently, arsenic is 
classified as a human carcinogen by the International Agency for Research on 
Cancer and the U.S. Environmental Protection Agency (Agency for Toxic 
Substances and Disease Registry 2011b; U.S. Environmental Protection 
Agency 2016).   
 
1.2.2: Case Studies of Arsenic Exposure 
 Most countries have drinking water sources that are contaminated 
with low levels of arsenic; however, case studies like Bangladesh and Chile 
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represent extreme situations where individuals consumed drinking water 
with arsenic levels far above the established standard of 10 μg/L for a 
prolonged period of time.   
 
1.2.2.1: Bangladesh 
 In the 1940s, tube wells were installed in Bangladesh, a highly 
populated and developing country, to provide inhabitants with a steady 
supply of drinking water free of microorganisms; in the past, consumption of 
contaminated surface water led to gastrointestinal problems, causing a 
significant amount of mortality for the inhabitants of Bangladesh.  By the 
early 1990s, millions of tube wells were constructed, providing drinking 
water to 80 percent of the population (Smith, Lingas, and Rahman 2000).   
 However, in 1993, it was discovered that the drinking water from the 
tube wells was contaminated with high levels of arsenic.  The concentration 
of arsenic in the drinking water ranged from 50 μg/L to 300 μg/L, 5 to 30 
times the standard established by the World Health Organization, depending 
on the location of the well.  Some of the health effects experienced by the 
inhabitants of Bangladesh included skin lesions, cancer of the bladder, 
kidney, and lungs, neurological problems, cardiovascular disease, and 
respiratory tract infections (Smith, Lingas, and Rahman 2000; Spivey 2011; 
Rahman et al. 2011).   
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 Even though the contaminated drinking water was identified in 1993, 
it is still an issue for Bangladesh.  Although monitoring programs have been 
set up, most communities are still drinking from the contaminated tube wells 
since it is their only source of clean water.  It is estimated that over 75 
million inhabitants of Bangladesh were or are presently exposed to high 
levels of arsenic in their drinking water (Smith, Lingas, and Rahman 2000).   
 
1.2.2.2: Northern Chile 
 Before 1958, the drinking water for Northern Chile was supplied by 
springs located in the Andes Mountains, which contained moderately high 
levels of inorganic arsenic, with concentrations around 90 μg/L.  In 1958, 
Region II of Chile switched its drinking water source to the Holajar and 
Toconce rivers (Marshall et al. 2007).  This resulted in drinking water with 
arsenic levels around 860 μg/L, over 80 times the standard established by the 
World Health Organization.  The drinking water remained contaminated 
with arsenic until the installation of a water treatment plant in 1971, which 
led to a significant decline in arsenic levels.  It is estimated that over 250,000 
inhabitants experienced the 13-year period of highly contaminated drinking 
water (Steinmaus et al. 2013; Marshall et al. 2007).   
 Northern Chile provides a great example to study how chronic 
exposure to arsenic results in adverse health outcomes since the arsenic 
levels were documented before, during, and after switching the drinking 
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water source.  Compared to other regions of Chile that sustained significantly 
lower arsenic levels in their drinking water, Region II inhabitants had an 
increased risk of mortality from bladder and lung cancer.  A study also 
suggested that mortality was greater for those inhabitants born during the 
13-year period of highly contaminated drinking water since deaths due to 
bladder and lung cancer continued to be elevated until the late 1990s 
(Steinmaus et al. 2013; Marshall et al. 2007; Smith et al. 1998).  
In addition to increased mortality from bladder and lung cancer, 
Region II of Chile had higher rates of deaths caused by acute myocardial 
infarction compared to other regions of Chile; when mortality from 
myocardial infarction was stratified by age, men who were born during the 
highest exposure period, experiencing arsenic-contaminated drinking water 
both in utero and during early childhood, had the highest rate ratio (Yuan et 
al. 2007).  Studies looking at the effects of arsenic exposure in utero and 
during early life have also noted an increase in mortality from bronchiectasis 
and chronic obstructive pulmonary disease in children born in Region II 
during the 13-year period (Smith et al. 2005).  Additional epidemiology 
studies conducted in Chile have indicated that high levels of arsenic resulted 
in increased mortality from infectious diseases including pulmonary 
tuberculosis (as reviewed by Dangleben, Skibola, and Smith 2013; Smith et 
al. 2011).   
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1.2.3: Arsenic Exposure and Birth Outcomes 
 Because of the prevalence of arsenic-contaminated drinking water, 
several epidemiology studies have been conducted to investigate the effects of 
the metalloid on pregnancy outcomes.  A cohort study in Bangladesh looked 
at the relationship between arsenic levels in drinking water and birth 
outcomes.  Results showed that arsenic concentrations greater than 50 μg/L 
significantly increased the risk for spontaneous abortion.  The study also 
found a dose-dependent relationship between arsenic exposure and risk of 
infant death (Rahman et al. 2007).  A cross-sectional study looking at the 
effects of contaminated tube wells in Bangladesh found similar results when 
examining the relationship between arsenic exposure during pregnancy and 
risk for adverse outcomes including spontaneous abortion and infant death 
(Milton et al. 2005).  Another cross-sectional study compared pregnancy 
outcomes between women exposed and unexposed to arsenic.  Women who 
were exposed to water with arsenic levels over 50 μg/L had significantly 
higher rates of adverse outcomes including preterm birth and stillbirth 
(Ahmad et al. 2001).   
 Additional studies have been conducted to assess the effects of in utero 
arsenic exposure on infantile infection rates.  A prospective cohort study done 
in the United States looked at how in utero arsenic exposure influenced the 
number and severity of infections during the first 4 months of life.  The study 
found a relationship between maternal urinary arsenic concentrations and 
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the number of respiratory tract infections in the infant including influenza 
and respiratory syncytial virus (relative risk=1.6, 95% confidence 
interval=1.0 to 2.5).  This study also discovered that arsenic levels were 
highly correlated with respiratory symptoms such as wheezing, coughing, 
fever, and diarrhea (relative risk=4.0, 95% confidence interval=1.0 to 15.8; 
Farzan et al. 2013).  A second prospective cohort study done in Bangladesh 
found similar results; in utero exposure to arsenic-contaminated drinking 
water increased the risk and severity of lower respiratory tract infections in 
infants during the first year of life (relative risk=1.69, 95% confidence 
interval=1.36 to 2.09; Rahman et al. 2011).   
 All of these studies determined that levels of arsenic above 50 μg/L 
have adverse consequences including an increased risk for spontaneous 
abortion, preterm birth, and stillbirth.  These studies also indicated that in 
utero arsenic exposure could lead to greater infant morbidity and mortality 
caused by respiratory infections and symptoms like diarrhea.  The increased 
risk for infantile infection and death could be related to the metalloid’s 
immunosuppressive property (Soto-Pena et al. 2006; Milton et al. 2017).  In 
addition, because arsenic easily crosses the placenta during early gestation to 
reach the fetus, neonates are especially vulnerable to exposure since they are 
undergoing rapid development and have only the initial components of an 
immune system (Vahter 2009; Hayward 1983).   
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1.2.4: Effects of Arsenic on the Immune System 
 In addition to being a known human carcinogen, arsenic also alters the 
function of the immune system (as reviewed by Attreed, Navas-Aciens, and 
Heaney 2017; as reviewed by Ratnaike 2003; Wu et al. 2003).  The role of the 
immune system is to protect the body by the neutralization and elimination 
of antigens.  The immune system is divided into innate and adaptive 
immunity.  Innate immunity refers to non-specific defense mechanisms that 
immediately go into action upon the presence of antigens in the body.  
Adaptive immunity is a specialized immune response targeted for specific 
antigens that the body recognizes from a previous exposure.  Both innate and 
adaptive immunity can be further divided into cellular and humoral 
immunity; cellular immunity involves different cells that can destroy 
antigens like T cells and lymphocytes, while humoral immunity refers to a 
response mediated by antibodies (as reviewed by Lee, Liao, and Yu 2011; 
Turvey and Broide 2010).   
 Studies have revealed that arsenic has numerous effects on the 
immune system.  In animal and human studies, arsenic lowered T-cell 
proliferation and diminished the phagocytic activity of the macrophage 
(Burns and Munson 1993; Banerjee et al. 2009; Lemarie et al. 2006).  In 
addition, nitric oxide release was lower and CD4+ cells from the spleen were 
higher for arsenic-exposed populations (Kumagai and Pi 2004; Gera et al. 
2017).  Furthermore, arsenic increased tumor burden in the lungs, liver, and 
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bladder in both animals and humans (Chen and Ahsan 2004; Wei et al. 2002; 
Cui et al. 2006).   
 Human population studies have identified notable effects of arsenic on 
the immune system.  Individuals exposed to arsenic through their drinking 
water have differences in expression for various genes responsible for 
immune function compared to those unexposed to arsenic-contaminated 
drinking water.  In a genome-wide expression study of peripheral blood 
mononuclear cells, arsenic exposure was linked to decreased expression of 
MHC class II molecules and inflammatory genes (Andrew et al. 2008).  In 
addition, arsenic was associated with the down regulation of cytokines 
including interleukin 1 beta, which plays an important role in cell signaling, 
as well as interleukin 2, which is necessary for a cell-mediated immune 
response (as reviewed by Attreed, Navas-Aciens, and Heaney 2017; Argos et 
al. 2006; Ahmed et al. 2014).   
 Arsenic has also been shown to change immune cell populations in 
humans.  Studies have revealed impaired lymphocyte function and 
proliferation, as well as decreased secretion of tumor necrosis factor alpha 
and various interleukins (Biswas et al. 2008).  Other studies have indicated 
that exposure to arsenic increases the number of eosinophils and decreases 
the number of monocytes compared to unexposed individuals.  Macrophage 
dysfunction, which involved reduced adhesion, lower nitric oxide production, 
and diminished phagocytic activity was also noted for individuals exposed to 
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arsenic (Banerjee et al. 2009).  In addition, blood samples from children 
exposed to high levels of arsenic through their drinking water have shown an 
increase in the release of granulocyte-macrophage colony stimulating factor, 
resulting in chronic inflammation.  This study in children has also identified 
lower CD4+ cell counts, resulting in a decreased CD4 to CD8 ratio, which 
may be an early indication of arsenic-mediated immunosuppression (Soto-
Pena et al. 2006).   
 Arsenic has also proven to have effects on humoral immunity, which 
involves an immune response modulated by antibodies.  Immunoglobulins or 
antibodies are proteins that recognize and bind to material that is foreign to 
the body (Solomon and Weiss 1995).  A study conducted in Bangladesh 
revealed significantly higher global IgG, IgA, and IgE levels in the serum for 
individuals suffering from respiratory conditions like asthma and bronchitis 
who were chronically exposed to arsenic-contaminated drinking water.  High 
levels of immunoglobulins could be an indication of a chronic infection, 
cancer, or an autoimmune disease (Islam et al. 2007).  Another study found 
elevated global IgG levels in the serum of pregnant women, but not in the 
umbilical cord serum, suggesting that arsenic inhibits the transport of IgG to 
the fetus (as reviewed by Attreed, Navas-Aciens, and Heaney 2017; Ser et al. 




1.2.5: Arsenic and Vaccine Immunogenicity 
 Vaccinations provide protection by priming the immune system to face 
future antigens.  When a vaccine is administered, the weakened or 
inactivated antigen enters the body and initiates an immune response.  The 
vaccine predominantly targets the humoral arm of the adaptive immune 
system to create antibodies against an antigen such as the influenza virus.  
After the vaccine is given, an individual is protected from a given antigen 
because their body has developed specific antibodies that will go into action 
upon the presence of the antigen (Clem 2011).   
 There are several types of vaccines in use.  Live-attenuated vaccines 
contain a weakened antigen that does not cause disease in individuals with 
functioning immune systems; examples of live-attenuated vaccines include 
the rubella and mumps vaccines.  Inactivated vaccines use dead viruses or 
bacteria to stimulate an immune response, consequently requiring multiple 
doses to build up immunity; an example of an inactivated vaccine is the polio 
vaccine.  Toxoid vaccines protect against bacterial diseases that produce 
toxins in the body by using a weakened toxin or toxoid; examples of toxoid 
vaccines include the diphtheria and tetanus vaccines.  Subunit vaccines 
contain only parts of a virus or bacteria, making side effects less common; the 
whooping cough vaccine is an example of a subunit vaccine.  Conjugate 
vaccines protect against bacteria that have an outer coating of 
polysaccharides, which makes the antigen difficult to recognize by an 
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immature immune system; the Haemophilus influenzae type B vaccine given 
to children is an example of a conjugated vaccine (Clem 2011; Centers for 
Disease Control and Prevention 2013).   
 Studies have suggested that arsenic can affect vaccine 
immunogenicity.  A study conducted in Bangladesh found that children 
exposed to arsenic-contaminated drinking water had increased plasma 
concentrations of global IgG and IgE compared to children unexposed to 
arsenic.  This same study identified decreasing levels of mumps-specific 
immunoglobulins that corresponded to increasing levels of arsenic, implying 
that the metalloid impairs the vaccine-mediated antigen-specific antibody 
response (Raqib et al. 2017).   
 Another study looking at participants of the National Health and 
Nutrition Examination Survey (NHANES) discovered that increased arsenic 
exposure, measured through metabolites in the urine, was correlated with 
higher total anti-hepatitis A antibodies for individuals who previously 
received immunization for the virus.  This study also noted greater 
seropositive status of hepatitis A with increasing levels of arsenic exposure, 
suggesting that the metalloid alters the immune response induced by the 
vaccine.  However, this study was not able to determine whether arsenic 
increased the rate of seroconversion for individuals previously immunized 
with the hepatitis A vaccine (Cardenas et al. 2016).   
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 A similar cross-sectional study using participants of NHANES 
examined the association between arsenic and varicella zoster virus IgG 
seroprevalence.  Using metabolites in the urine to determine arsenic 
exposure, the study found an inverse relationship between total urinary 
arsenic and negative varicella zoster virus IgG for both vaccinated and non-
vaccinated individuals.  These results suggest that the immunosuppressive 
properties of arsenic can decrease both natural and vaccine-mediated 
immunity to the varicella zoster virus (Cardenas et al. 2015).   
 A different study conducted on Bangladeshi children looked at how the 
antibody response to vaccines was modified by arsenic exposure.  The study 
discovered that arsenic in the drinking water did not negatively alter the 
antibody response to the cholera vaccine, as well as the diphtheria or tetanus 
vaccines.  In addition, this study did not find any differences in the levels of 
measles-specific immunoglobulins between exposed and unexposed children 
(Saha et al. 2013).   
 
1.2.6: Impact of Influenza 
 Influenza is a highly contagious respiratory infection caused by an 
influenza virus.  Symptoms can vary widely but typically include fever, 
muscle aches, nasal congestion, and a persistent cough.  Each year in the 
United States, it is estimated that the number of influenza cases ranges from 
9.3 million to 49.0 million, and the number of deaths attributed to influenza 
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ranges from 12,000 to 79,000 (Centers for Disease Control and Prevention 
2019a).  Vulnerable populations including children under the age of 5, adults 
over the age of 65, and pregnant women are at the greatest risk for 
developing influenza-related complications such as pneumonia and multi-
organ inflammation.  To prevent the spread of influenza, as well as to 
decrease the severity of the illness, the Centers for Disease Control and 
Prevention recommends that every individual over the age of 6 months 
should receive the flu vaccine each year (Centers for Disease Control and 
Prevention 2018b).  The seasonal influenza vaccine is available in many 
forms including an inactivated vaccine, a live-attenuated nasal spray, and an 
adjuvant vaccine; the type of influenza vaccine administered depends on a 
variety of factors including age, immune status, and medical history (Centers 
for Disease Control and Prevention 2018a; Chung et al. 2019).  The influenza 
virus can be spread through a variety of different ways, but exposure to 
environmental contaminants such as arsenic could increase an individual’s 
susceptibility to infection by altering the immune response (Liao et al. 2011).   
 The influenza virus is a RNA virus that encompasses three different 
subtypes: influenza A, influenza B, and influenza C.  The three subtypes 
differ in host range and pathogenicity, with influenza A primarily infecting 
mammals including humans (Taubenberger and Morens 2008).  Influenza A 
is further characterized by two surface glycoproteins, hemagglutinin (HA) 
and neuraminidase (NA), that project from the virion.  Although there are 16 
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HA and 9 NA glycoproteins, only 3 subtypes of HA and 2 subtypes of NA have 
been known to cause human influenza epidemics (Taubenberger and Morens 
2008; Bouvier and Palese 2008).   
 There have been several influenza pandemics over the past century 
including the 1918 H1N1 Spanish Flu and the 1957 H2N2 Asian Flu (Potter 
2001; Saunders-Hastings and Krewski 2016).  The most recent pandemic was 
the 2009 Swine-Origin Pandemic.  In April of 2009, a novel H1N1 influenza 
virus was isolated from humans in California and Mexico.  The composition of 
the virus resulted from the exchange of gene segments between the North 
American H3N2 and H1N2 swine viruses, and the Eurasian avian-like swine 
viruses (Figure 2; Garten et al. 2009; Neumann, Noda, and Kawaoka 2009).  
Overall, 214 countries and territories had confirmed cases of the 2009 H1N1 
influenza.  In the United States alone, the number of cases ranged from 43 
million to 89 million, and the number of deaths ranged from 8,870 to 18,300 
(Centers for Disease Control and Prevention 2010).  In addition, 80 percent of 
the deaths attributed to the 2009 H1N1 pandemic occurred in individuals 
under the age of 65; during a typical influenza epidemic, over 80 percent of 




Figure 2: Genesis of swine-origin H1N1 influenza viruses (Neumann, Koda, 
and Kawaoka 2009).  
 
1.2.7: Effects of Arsenic on Influenza Susceptibility 
 Some studies have linked arsenic exposure with an increased risk of 
developing respiratory infections such as influenza.  One study exposed mice 
to arsenic both in utero and during postnatal life to determine if exposure to 
the metalloid alters the inflammatory response to H3N1 influenza A virus 
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infection.  The results of the study indicated that in utero and early life 
arsenic exposure reduces the inflammatory response to influenza A virus by 
increasing the number of neutrophils, lymphocytes, and macrophages in 
bronchoalveolar lavage fluid.  This study also discovered that arsenic 
exposure was associated with increased viral titers for influenza A virus.  In 
addition, both male and female mice exposed to arsenic had notable adverse 
differences in lung structure and airway resistance, similar to those with 
bronchiectasis (Ramsey et al. 2013a).  The results from this study 
demonstrated how arsenic exposure could potentially result in greater 
susceptibility to respiratory problems like influenza and bronchiectasis.  In 
addition, the results suggest that exposure to arsenic in utero and during 
early life could effect the development of airway structure, resulting in an 
exacerbated inflammatory response to respiratory infections acquired in the 
future.   
 A study conducted in Taiwan, West Bengal, and the United States 
used a mathematical model to determine whether arsenic exposure decreases 
lung function and increases influenza susceptibility.  It was discovered that 
exposure to arsenic decreases forced expiratory volume in one second, a 
respiratory metric that measures lung function and detects respiratory 
diseases like pulmonary fibrosis and emphysema.  The model also revealed 
that chronic arsenic exposure and influenza A virus infection poses a 
significant risk to decreased lung function (Liao et al. 2011).   
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 Another study used an adult mouse model to investigate the overall 
effects of arsenic on H1N1 influenza A virus infection.  Results from the 
study performed in male mice showed that mice exposed to arsenic had 
increased morbidity, measured through body weight, after infection with the 
influenza A virus compared to the control group; the mice that were given 
arsenic lost a significant amount of weight while the unexposed mice 
experienced moderate weight loss, but recovered several days post infection.  
The exposed group also had a significant increase in viral titer, as well as 
histological changes including hemorrhage and edema compared to the 
unexposed group.  Furthermore, the study discovered reduced cytokine 
production and decreased dendritic cells in lymph nodes of arsenic-exposed 
mice (Kozul et al. 2009).   
 
1.2.8: Gaps in the Research 
 Although the effects of arsenic have been extensively explored, there 
are still knowledge gaps that should be addressed.  First, a more concrete 
understanding about how arsenic exposure influences the immune system is 
needed.  Several studies have suggested that arsenic alters the immune 
system, but the mechanisms driving these effects are still unknown (Banerjee 
et al. 2009; Gera et al. 2017).  Additional information and studies are also 
needed to develop a more explicit dose-response relationship between arsenic 
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exposure and quantifiable changes in the immune system such as cytokine 
and antibody production.   
 Another significant knowledge gap is understanding how in utero 
exposure to arsenic influences the development of the immune system during 
both infancy and early childhood.  Many studies have looked at the 
relationship between arsenic exposure and pregnancy outcomes, but few 
studies have investigated the effects of in utero exposure on infectious disease 
susceptibility in the offspring (Ahmad et al. 2001; Rahman et al. 2007).  
Addressing this gap in knowledge is critical because children are particularly 
vulnerable since they are still undergoing development and have an 
immature immune system (as reviewed by Ygberg and Nilsson 2011; as 
reviewed by Simon, Hollander, and McMichael 2015).  In addition, arsenic-
contaminated drinking water is a prevalent issue, especially in developing 
countries where infectious diseases are the primary cause of death (Jones et 
al. 2008).   
 A third knowledge gap involves understanding how in utero exposure 
to arsenic alters vaccine efficacy.  Studies have looked at how chronic arsenic 
exposure influences vaccine immunogenicity; however, no studies have 
investigated how in utero arsenic exposure affects the developing immune 
system and immunological memory responses in infants (as reviewed by 
Attreed, Navas-Aciens, and Heaney 2017; Raqib et al. 2017).  Information on 
in utero arsenic exposure during important developmental windows for the 
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immune system could provide valuable knowledge to the field of public 
health.   
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PART 2: RESEARCH QUESTION AND SPECIFIC AIMS 
 
2.1: Research Question 
 As mentioned previously, there are several knowledge gaps in the field 
of arsenic exposure, especially when looking at the metalloid as an 
immunotoxin.  For my project, I used a mouse model to investigate how in 
utero arsenic exposure influences birth outcomes and affects influenza A 
virus vaccine immunogenicity in the offspring.   
 
2.2: Specific Aim 1 
 The goal for Specific Aim 1 was to determine how in utero arsenic 
exposure influences birth outcomes in the mice. Outcomes including 
reproductive success, fetal resorption, neonatal outcomes, and pup size were 
measured and compared.   
 
2.3: Specific Aim 2 
 The goal for Specific Aim 2 was to determine the effects of in utero 
arsenic exposure on early life influenza A virus vaccine immunogenicity and 
subsequent infection susceptibility during adulthood.  After in utero exposure 
to arsenic, the pups were vaccinated during the juvenile life stage, and then 
challenged with the drift variant of the influenza A virus (Figure 3).  The 
pups were monitored to measure severity of the infection through changes in 
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body weight, temperature, and clinical scores.  In addition, immunoassays 
were performed on serum samples to assess the abundance and functionality 
of influenza A virus-specific immunoglobulins (Yu et al. 2002; Mazanec, 
Coudret, and Fletcher 1995; Edenborough, Gilbertson, and Brown, 2012; 








Figure 3: Experimental timeline for specific aim 2. 
 
2.4: Public Health Significance 
 Arsenic-contaminated drinking water is a massive public health 
problem since millions of people are exposed to levels that far exceed the 
World Health Organization standard of 10 μg/L.  Especially in countries such 
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as Chile and Bangladesh, extremely high arsenic levels are resulting in 
adverse health outcomes.  In addition, arsenic is a harmful metalloid that is a 
known human carcinogen, as well as a developmental toxin and 
immunotoxin.  Looking within the field of public health, arsenic-
contaminated drinking water is also an environmental health problem.  As 
the climate begins to change, drinking water resources will become limited 
and less accessible, particularly in developing countries.  These countries will 
have to rely on alternative or unconventional resources such as tube wells, 
which may have high arsenic levels, depending on geological composition of 
the location, for a steady supply of drinking water.  In addition, as the 
climate warms and precipitation patterns change, infectious diseases like 
influenza will become more prevalent, especially in developing countries 
where individuals with compromised immune systems will be challenged 
(Harper et al. 2011).   
This innovative project was the first study to investigate how in utero 
arsenic exposure alters the offspring’s humoral immune response to the 
influenza A virus vaccine.  This project not only addressed knowledge gaps 
regarding arsenic-contaminated drinking water by providing more insight on 
how in utero exposure influences birth outcomes, but also uncovered how 
influenza A virus vaccine immunogenicity during early life changes based on 
in utero arsenic exposure.   
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 The results from this study can be applied to better predict and 
prepare for the outcomes associated with in utero exposure to arsenic 
including an increased risk for influenza A virus infection.  By having a 
greater understanding of how arsenic alters vaccine immunogenicity during 
early life, appropriate vaccination strategies can be applied to ensure 
protection from influenza-related morbidity and mortality, especially in 
young children exposed to arsenic in utero.   
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PART 3: MATERIALS AND METHODS 
 
3.1: Animal Care 
 Adult (7 to 8 week old) male and female C57BL/6J mice were 
purchased from The Jackson Laboratory (Bar Harbor, ME).  This specific 
strain of mouse was chosen because it is a commonly used model in influenza 
research (Bouvier and Lowen 2010; Thangavel and Bouvier 2014).  For 
mating purposes, male mice were housed individually, while female mice 
were housed 2 per cage.  All animals were housed in microisolator cages with 
corncob bedding, and kept in a facility with a 14-hour light/10-hour dark 
cycle.  In addition, females were provided with extra cotton nestlets and 
plastic mouse houses for enrichment.  Food and water were provided ad 
libitum.  Johns Hopkins University Animal Care and Use Committee 
approved all animal procedures under protocol M017H323.   
 
3.2: Arsenic Exposure 
 Arsenic stock solution was made by dissolving sodium meta-arsenite 
(Sigma-Aldrich) into arsenic-free drinking water (Crystal Geyser).  The 
arsenic stock was diluted to create a solution with a final concentration of 100 
μg/L or ppb.   
 Glass water bottles were filled with either arsenic treated water (100 
ppb) or arsenic free water (0 ppb) and placed in the cages housing female 
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mice; females were exposed to treated water for 1 to 2 weeks prior to mating.  
Males were not provided with treated water, and instead were exposed to the 
facility drinking water.  In addition, both males and females were given 
special animal feed containing low amounts of arsenic (Research Diets Inc.) 
to limit the intake of the metalloid from sources other than the drinking 
water.  Twice a week, water bottles and food were replaced, and the amount 
of water and food consumed was recorded.   
 
3.3: Timed Mating 
 Three days before timed mating, bedding was swapped between male 
and female cages to synchronize the estrous cycle to increase reproductive 
success (Byers et al. 2012).  On the day of mating, 2 cohoused females were 
placed in the male cage, along with the treatment water bottle; the animals 
were allowed to mate overnight.  The following morning, which marks 
gestation day 0, the females were taken out and placed back in their original 
cage with the treatment water bottle.  The female mice were weighed on 
gestation day 10, and pregnancy was confirmed by a weight increase of ~2 
grams from gestation day 0 (Heyne et al. 2015; Mader et al. 2009; Pauley and 
Washington 2017).   
 Mating occurred in 2 consecutive waves.  After the 1st wave of mating, 
a 2nd wave of mating using non-pregnant females from the 1st wave of mating 
occurred during the following week.  During both waves, the 2 cohoused 
 29 
females were paired with the same male to increase successful mating and to 
decrease the chance of spontaneous abortion (Gangrade and Dominic 1984; 
Kumar and Dominic 1993; Eccard, Dammhahn, and Ylonen 2017).  If it was 
discovered that 2 pregnant females were cohoused in 1 cage, 1 of the females 
was placed in her own cage between gestation day 15 and 16.  Throughout 
pregnancy, the female dams were continuously exposed to either 0 ppb or 100 
ppb arsenic water to model in utero exposure.   
 
3.4: Gestation Day 17 Euthanasia 
 To further look at the effects of arsenic on birth outcomes, females 
were mated for a gestation day 17 euthanasia.  Female mice (10 weeks old) 
were exposed to either arsenic treated water (100 ppb) or arsenic free water 
(0 ppb) for 2 weeks.  The females were then mated with males using the same 
protocol employed previously.  The females were weighed on gestation day 10, 
and pregnancy was confirmed by a weight increase of ~2 grams from 
gestation day 0 (Heyne et al. 2015; Mader et al. 2009; Pauley and 
Washington 2017).  Throughout pregnancy, females were continuously given 
treated water to model in utero exposure.   
 On gestation day 17, 2 days prior to delivery of pups, the pregnant 
females were euthanized by the inhalation of isoflurane.  Following blood 
collection from the dam, the entire uterine horn was removed from the 
abdomen and placed in ice-cold phosphate-buffered saline (PBS).  The 
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number of offspring and fetal resorptions was noted, and a section of the right 
uterine horn was placed in zinc formalin for future histological analysis.  
Fetuses were then individually dissected out of the uterine horn, and the 
placenta and umbilical cord were removed from the fetus; the exterior 
membrane covering the placenta was clipped and the tissue was weighed 
(Klaunberg et al. 2004; Pritchett et al. 2005).  Next, weight and crown-to-
rump length of the fetus were measured and recorded.  Lungs and heart of 
the fetus were isolated and weighed.  All of the tissue was snap frozen in 
liquid nitrogen for future gene and protein expression work, as well as for 
arsenic speciation analysis.   
 
3.5: Delivery and Weaning of Pups 
 Between gestation day 19 and 21, female dams delivered pups (Murray 
et al. 2010; McCarthy et al. 2018).  On the day of delivery, exposure to arsenic 
stopped and treatment water bottles were all changed to 0 ppb water.  One 
week post birth, the pups were counted and sexed, and any pups lost to 
cannibalism were noted.  In addition, weight and crown-to-rump length were 
measured (Rhees and Atchley 2000).   
 At 4 weeks post birth, pups were weaned.  The offspring were weighed 
and ear-punched.  Males and females were housed up to 5 littermates per 
cage.  The offspring were provided with facility drinking water and animal 
feed containing low amounts of arsenic ad libitum.   
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3.6: Synthesis of Influenza A Virus Vaccine 
 A mouse-adapted (ma) 2009 H1N1 strain of IAV synthesized by the lab 
of Dr. Andrew Pekosz (Johns Hopkins Bloomberg School of Public Health) 
was used for vaccination.  Madin-Darby Canine Kidney (MDCK) cells were 
infected with viral media containing the ma2009 H1N1 IAV at a multiplicity 
of infection of 0.01.  After a 4 day incubation at 32C, the infected cells were 
harvested and centrifuged to remove cell debris.  Following centrifugation, 
beta-propiolactone was added to inactivate the virus.  The infected cells were 
then purified by ultracentrifugation with a sucrose layer.  The viral protein 
pellet was then resuspended in PBS containing calcium and magnesium to 
create the vaccine stock (Fink et al. 2018).   
 To determine the concentration of viral protein in the vaccine stock, a 
Pierce bicinchoninic acid (BCA) assay was performed (Thermo Scientific).  
After diluting by a factor of four and eight, the concentration of the viral 
protein was calculated by averaging the values and multiplying by the 
dilution factor.  
 
3.7: Booster Strategy Vaccination 
 At 2 and 5 weeks post birth, the offspring were vaccinated with the 
inactivated ma2009 H1N1 IAV vaccine.  On the day of vaccination, the 
vaccine stock was thawed and diluted with sterile PBS to a specific viral 
protein concentration.  The offspring were then immunized with 100 μL/dose 
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of vaccine by intraperitoneal injection.  Pups from the 1st wave of mating 
received 17.99 μg/dose for the first vaccination and 33.22 μg/dose for the 
second vaccination.  Pups from the 2nd wave of mating received 32.16 μg/dose 
for the first vaccination and 36.19 μg/dose for the second vaccination (Table 
1).   
 
Table 1: Vaccine concentrations used to immunize offspring from the 1st and 
2nd waves of mating.  
Mating Wave Vaccination 1 Vaccination 2 
1 17.99 μg/dose 33.22 μg/dose 
2 32.16 μg/dose 36.19 μg/dose 
 
 From the 2nd wave of mating, 2 male and 2 female offspring from each 
treatment group acted as unvaccinated controls.  On the day of the first 
vaccination, the offspring were randomly designated as controls and tagged 
by ear-punch.   
 
3.8: Pre-Challenge Blood Collection 
 At 21 days post vaccination 2 and before challenge with the drift 
variant IAV, blood was collected from the offspring.  Samples were collected 
by facial bleeds through the submandibular vein (Golde, Gollobin, and 
Rodriguez 2005; Regan et al. 2016).  These blood samples were spun down at 
10,000 x gravity for 10 minutes to obtain serum.   
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3.9: Enzyme-Linked Immunosorbent Assay (ELISA) 
 To compare IgG, IgG1, and IgG2a/c titers against the ma2009 H1N1 
IAV vaccine strain, ELISAs were performed on pre-challenge serum samples 
that were collected 21 days post vaccination 2 (Fink et al. 2018).  Before 
running the assay, 96-well plates were coated with purified ma2009 H1N1 
IAV protein diluted in ELISA coating buffer.   
The following day, the plates were blocked with a mixture of milk 
powder and ELISA wash buffer, and incubated for 1 hour at 37C.  During the 
incubation, the serum samples were serially diluted in a solution of wash 
buffer, milk power and bovine serum albumin (BSA).  After removing the 
blocking buffer, the diluted samples were added to the plates in duplicate and 
incubated for 1 hour at 37C.  Following the incubation, the plates were 
washed with wash buffer and the peroxidase-conjugated secondary antibody 
(Invitrogen), was added.  After another 1 hour incubation at 37C, the plates 
were washed and 3, 3’, 5, 5’-tetramethylbenzidine (Sigma) was added to each 
plate to react with the peroxidase-conjugated secondary antibody.  After a 20 
minute incubation at room temperature, stop solution containing 1N 
hydrochloric acid was layered on top of each well, and the plates were read at 
450 nanometers.  Titers were determined as the highest dilution with an 
absorbance value 3 times greater than the average absorbance of the 
negative control.   
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3.10: Neutralizing Antibody Assay 
 To measure the functionality of antibodies against the drift variant 
ma2009 H1N1 IAV virus, neutralizing antibody assays were performed on 
pre-challenge serum samples that were collected 21 days post vaccination 2 
(Fink et al. 2018).  Before running the assay, 96-well plates were seeded with 
MDCK cells.  When the plates were 100 percent or over confluent, the assay 
was started.   
 Infectious media containing Dulbecco’s Modified Eagle’s Medium 
(DMEM), BSA, and N-acetyl trypsin was made.  An aliquot of the infectious 
media was used to create the viral media, which contained the drift variant 
ma2009 H1N1 IAV virus.  Heat-inactivated serum samples were serially 
diluted in infectious media, and then viral media was layered on top; the 
samples were incubated at room temperature for 1 hour.  During this time, 
the TCID50 back-titer plate was prepared by serially diluting the viral media 
in infectious media.  The MDCK cell media was removed from the plates, 
followed by washes with PBS containing calcium and magnesium.  The serum 
sample dilutions suspended in viral media were then plated in replicates of 4 
and incubated for 24 hours at 32C.   
 Following the incubation, the media was removed and the plates were 
washed with PBS containing calcium and magnesium.  New infectious media 
was added, and the plates were incubated for 6 days at 32C.   
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 After the 6 day incubation, the media was dumped out and the plates 
were fixed with zinc formalin.  The plates were then stained with naphthol 
blue black.  After washing with deionized water, the neutralizing antibody 
titer was calculated as the highest dilution that did not show cytopathic 
effects (CPE) in 50 percent of the wells.   
 
3.11: Challenge with the Drift Variant Influenza A Virus 
 At 8 weeks post birth and 3 week following vaccination 2, the offspring 
were challenged with the drift variant ma2009 H1N1 IAV containing a 
K166Q mutation on the hemagglutinin glycoprotein; challenging with the 
drift variant mimics the seasonal discrepancy between IAV vaccine strains 
and circulating IAV infectious strains in human populations (Fink et al. 
2018. Linderman et al. 2014; Castelan-Vega et al. 2014; Yasuhara et al. 
2017).  On the day of the challenge, body weight and temperature were 
recorded as a baseline measurement.  The infection solution was made by 
diluting the drift variant viral stock generated by the lab of Dr. Sabra Klein 
(Johns Hopkins Bloomberg School of Public Health) in sterile DMEM to reach 
a lethal tissue culture infectious dose 50 (TCID50) of 105.  Two aliquots of the 
infection solution were placed on ice, while the third aliquot was preserved at 
-80C for future titering.   
 The offspring were anesthetized with a sub-lethal dose of a 
ketamine/xylazine mixture by intraperitoneal injection.  The dose used for 
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anesthetizing was determined by body weight; mice under 20 grams received 
75 μL of the drug cocktail while mice over 20 grams were given 100 μL of the 
drug cocktail.  After ensuring the animals were completely anesthetized, they 
were placed on a heating pad to prevent heat loss, and lubricant was added to 
the eyes to prevent drying.  The offspring were then intranasally inoculated 
by administering 30 μL of the infection solution into the nasal cavity.  The 
infection solution was slowly added drop-wise, allowing the mouse to inhale 
each drop and alternating nostrils to ensure even distribution of the virus 
into both lungs.   
 From the 1st wave of mating, 2 male and 2 female offspring from each 
treatment group acted as unchallenged controls; these mice were sham 
infected by intranasally inoculating with 30 μL of sterile PBS.  In addition, 
the unvaccinated controls from the 2nd wave of mating were sham infected 
with the same volume of PBS.   
 Following challenge with the drift variant ma2009 H1N1 IAV, body 
weight and temperature were measured daily.  As stated in the protocol 
approved by the Animal Care and Use Committee, if during the disease 
course the offspring lost more than 35 percent of their initial body weight or 
10 percent of their initial temperature, they were euthanized.  In addition, 
morbidity following challenge was measured by the presentation of clinical 
signs including piloerection, hunched posture, lack of an escape response, and 
dyspnea (Foltz and Ullman-Cullere 1999; Burkholder et al. 2012).   
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3.12: Animal Euthanasia and Tissue Collection 
 At different points during the disease course (1, 3, 5, and 28 days post 
challenge), the offspring were euthanized and tissue samples were collected.  
Animals were euthanized by the inhalation of isoflurane and subsequent 
rupture of the diaphragm.   
 Blood, lungs, spleen, thymus, and mediastinal lymph nodes were 
collected from the animals.  Blood was collected through the inferior vena 
cava, and then spun down at 10,000 x gravity for 10 minutes to obtain serum.  
The entire left lung of the animal was homogenized using tissue dissociator 
C-tubes (Miltenyi Biotec) and preserved in cryopreservation media containing 
fetal bovine serum (FBS) and dimethyl sulfoxide (DMSO).  The superior, 
middle, and inferior lobes of the right lung were snap frozen for prospective 
TCID50 assays to measure viral concentration.  The post-caval lobe of the 
right lung was placed in RNAprotect (Qiagen) for future work on gene and 
protein expression.  The spleen, thymus, and mediastinal lymph nodes were 
homogenized using frosted microscope slides and preserved in 
cryopreservation media for immune cell analysis by flow cytometry.   
 
3.13: Statistical Analysis 
 Differences in birth outcomes including reproductive success, litter 
size, and proportion of males to females between treatment groups were 
analyzed using Student’s t-test.  Data collected from the gestation day 17 
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euthanasia was also analyzed using Student’s t-test.  Results such as pre-
challenge IgG and neutralizing antibody titers were graphed using Prism 
(GraphPad) and compared using two-way ANOVAs with multiple 
comparisons.  Body weight and temperature change following challenge was 
analyzed and compared using non-linear regression.  Differences were 
considered statistically significant if the P-value < 0.05.   
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PART 4: RESULTS 
 
4.1: Reproductive Success and Birth Outcomes 
4.1.1: Reproductive Success 
 Pregnancy was confirmed by a weight gain of more than 2 grams by 
gestation day 10 (Heyne et al. 2015; Mader et al. 2009; Pauley and 
Washington 2017).  From the 1st wave of mating, there were 3 pregnancies 
from the 0 ppb treatment group and 3 pregnancies from the 100 ppb 
treatment group (Table 2).  From the 2nd wave of mating, there were 6 
pregnancies from the 0 ppb treatment group and 4 pregnancies from the 100 
ppb treatment group (Table 3).  By pooling the data from the 1st and 2nd 
waves, the percent of successful pregnancies for the 0 ppb group was 47.4 
percent, while the percent of successful pregnancies for the 100 ppb group 
was 36.8 percent (Table 6); the difference in number of successful pregnancies 
was not statistically significant between the two treatment groups (P=0.52, 
95% confidence interval=-0.44 to 0.23).  In addition, all litters from both 
waves of mating were delivered on gestation day 19, which is within the 
range of expected gestation length (Murray et al. 2010; McCarthy et al. 2018).   
 
Table 2: Reproductive success for the 1st wave of mating; no significance. 
Treatment 
# of Animals 
Mated 
# of Successful 
Pregnancies 
% of Successful 
Pregnancies 
0 ppb 19 3 15.8% 
100 ppb 19 3 15.8% 
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Table 3: Reproductive success for the 2nd wave of mating; no significance.  
Treatment 
# of Animals 
Mated 
# of Successful 
Pregnancies 
% of Successful 
Pregnancies 
0 ppb 16 6 37.5% 
100 ppb 16 4 25% 
 
4.1.2: Litter Size 
 For the 1st wave of mating, litter size from the 0 ppb treatment group 
ranged from 4 to 10 pups, with an average of 7 pups per litter; litters from 
the 100 ppb treatment group ranged from 7 to 8 pups, with an average of 7.3 
pups per litter (Table 4).  For the 2nd wave of mating, litter size from the 0 
ppb group ranged from 2 to 9 pups, with an average of 5.7 pups per litter, 
while litters from the 100 ppb group ranged from 4 to 10 pups, with an 
average of 7.5 pups per litter (Table 5).  By pooling the data from the 1st and 
2nd waves, the average litter size for the 0 ppb treatment group was 6.1 pups 
and the average litter size for the 100 ppb treatment group was 7.4 pups 
(Table 6); the difference in litter size between the two treatment groups was 
not statistically significant (P=0.28, 95% confidence interval=-1.21 to 3.85).   
 From the 2nd wave of mating, 2 pups from the 0 ppb group and 1 pup 
from the 100 ppb group were lost to cannibalism during the first week 
following birth.  This was perhaps due to stress, caused by excessive noise 
and vibration, following delivery of the pups (Lane-Petter 1968; Poley 1974).  
In addition, pup cannibalism is more common in nulliparous females (Weber, 
Olsson, and Algers 2007; Weber et al. 2013).   
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4.1.3: Proportion of Males to Females 
 One week following birth, pups were sexed.  For the 0 ppb group from 
the 1st wave of mating, the number of males in each litter ranged from 3 to 8, 
while the number of females in each litter ranged from 1 to 4.  For the 100 
ppb group from the 1st wave of mating, the number of males per litter ranged 
from 3 to 6 and the number of females per litter ranged from 2 to 4. Overall 
from the 1st wave of mating, there were 14 male pups and 7 female pups from 
the 0 ppb treatment group, and 12 male pups and 10 female pups from the 
100 ppb treatment group (Table 4).   
 From the 2nd wave of mating, the number of males per litter ranged 
from 2 to 5, while the number of females per litter ranged from 1 to 4 for the 
0 ppb treatment group.  For the 100 ppb treatment group from the 2nd wave 
of mating, the number of males in each litter ranged from 1 to 6, and the 
number of females in each litter ranged from 2 to 5.  Overall from the 2nd 
wave of mating, there were 19 male pups and 13 female pups from the 0 ppb 
group, and 17 male pups and 12 female pups from the 100 ppb group (Table 
5).   
 By pooling the data from the 1st and 2nd waves of mating for the 0 ppb 
treatment group, the total number of male pups was 33 and the total number 
of female pups was 20, a difference that was statistically significant (P=0.05, 
95% confidence interval=-3.27 to 0.02).  However, by pooling the data for the 
100 ppb treatment group, the total number of male pups was 29 and the total 
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number of female pups was 22 (Table 6); this difference was not statistically 
significant (P=0.26, 95% confidence interval=-2.83 to 0.83).   
 


















0 ppb 3 7 14 5 7 3 
100 ppb 3 7.3 12 3 10 2 
 


















0 ppb 6 5.7 19 3 13 3 
100 ppb 4 7.5 17 5 12 3 
 
Table 6: Birth outcomes data pooled from the 1st and 2nd waves of mating; no 
significance.  
Treatment 




Total # of 
Male Pups 
Total # of 
Female Pups 
0 ppb 47.4% 6.1 33 20 
100 ppb 36.8% 7.4 29 22 
 
4.1.4: Weight and Length of Pups at 1 Week of Age 
 One week following birth, the offspring were measured for weight and 
crown-to-rump length.  For male pups from the 1st wave of mating, the 
average weight was 3.31 grams and the average length was 35.24 
centimeters for the 0 ppb treatment group. For male pups from the 100 ppb 
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treatment group, the average weight was 3.09 grams and the average length 
was 33.83 centimeters (Table 7).  The difference in both weight and length of 
male pups between treatment groups was statistically significant (P=0.05, 
95% confidence interval=-0.43 to 0.00 and P=0.05, 95% confidence interval=-
2.81 to -0.01 respectively).  For female pups from the 1st wave of mating, the 
average weight was 3.01 grams and the average length was 33.69 
centimeters for the 0 ppb treatment group.  For female pups from the 100 ppb 
treatment group, the average weight was 3.03 grams and the average length 
was 32.60 centimeters (Table 7).  The difference in both weight and length of 
female pups between treatment groups was not significant (P=0.87, 95% 
confidence interval=-0.28 to 0.32 and P=0.09, 95% confidence interval=-2.38 
to 0.21 respectively).   
 From the 2nd wave of mating, the average weight was 3.13 grams and 
the average length was 35.37 centimeters for male pups from the 0 ppb 
group.  The average weight was 3.30 grams and the average length was 34.73 
centimeters for male pups from the 100 ppb group (Table 8).  The difference 
in both weight and length of male pups between treatment groups was not 
significant (P=0.99, 95% confidence interval=-0.23 to 0.23 and P=0.25, 95% 
confidence interval=-1.75 to 0.48 respectively).  For female pups from the 2nd 
wave of mating, the average weight was 3.24 grams and the average length 
was 34.82 centimeters for the 0 ppb treatment group, while the average 
weight was 3.19 grams and the average length was 34.88 centimeters for the 
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100 ppb treatment group (Table 8).  The difference in both weight and length 
of female pups between treatment groups was not significant (P=0.71, 95% 
confidence interval=-0.32 to 0.22 and P=0.93, 95% confidence interval=-1.36 
to 1.48 respectively).   
 By pooling the data for male pups in the 0 ppb treatment group, the 
average weight was 3.30 grams and the average length was 35.31 
centimeters, while the average weight was 3.21 grams and the average 
length was 34.36 centimeters for male pups from the 100 ppb treatment 
group (Table 9).  The difference in weight for male pups between treatment 
groups was not significant (P=0.26, 95% confidence interval=-0.25 to 0.07); 
however, the difference in crown-to-rump length was significant (P=0.03, 95% 
confidence interval=-1.81 to -0.10).  By pooling the data for female pups in the 
control group, the average weight was 3.16 grams and the average length 
was 34.42 centimeters, while the average weight was 3.12 grams and the 
average length was 33.84 centimeters for female pups from the arsenic group 
(Table 9).  Although the average weight and average length for the 
experimental group were lower compared to the control group, the difference 
was not significant (P=0.68, 95% confidence interval=-0.24 to 0.16 and 
P=0.30, 95% confidence interval=-1.68 to 0.52 respectively).   
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Table 7: Weight and crown-to-rump length averages at 1 week of age for the 
1st wave of mating, stratified by sex.  N=7-14 pups from 3 litters; P < 0.10 
indicated by † and statistical significance indicated by *P < 0.05.  
Treatment 
Average Weight 
of Male Pups (g) 
Average Length 
of Male Pups 
(cm) 
Average Weight 
of Female Pups 
(g) 
Average Length 
of Female Pups 
(cm) 
0 ppb 3.31 35.24 3.01 33.69 
100 ppb 3.09* 33.83* 3.03 32.60† 
 
Table 8: Weight and crown-to-rump length averages at 1 week of age for the 




of Male Pups (g) 
Average Length 
of Male Pups 
(cm) 
Average Weight 
of Female Pups 
(g) 
Average Length 
of Female Pups 
(cm) 
0 ppb 3.13 35.37 3.24 34.82 
100 ppb 3.30 34.73 3.19 34.88 
 
Table 9: Pooled weight and crown-to-rump length averages at 1 week of age 
for the 1st and 2nd waves of mating, stratified by sex.  N=20-33 pups from 7 to 
8 litters; statistical significance indicated by *P < 0.05.  
Treatment 
Average Weight 
of Male Pups (g) 
Average Length 
of Male Pups 
(cm) 
Average Weight 
of Female Pups 
(g) 
Average Length 
of Female Pups 
(cm) 
0 ppb 3.30 35.31 3.16 34.42 





4.2: Gestation Day 17 Euthanasia 
 There were 10 females from the 0 ppb treatment group that did not get 
pregnant during the 1st or 2nd waves of mating.  In preparation for the 
gestation day 17 euthanasia, 5 females were exposed to 0 ppb treated water 
and 5 females were exposed to 100 ppb treated water for 2 weeks prior to 
mating.  After mating, 2 females from the 0 ppb group and 1 female from the 
100 ppb group were confirmed to be pregnant.   
 
4.2.1: Litter Size and Fetal Resorptions 
 The first litter from the control group had a total of 2 fetuses with 1 
fetal resorption, indicated by necrotic placental tissue in the uterine horn 
(Ward, Elmore, and Foley 2012; Flores et al. 2014; Miner et al. 2016).  The 
second litter from the control group had a total of 7 fetuses with 1 fetal 
resorption.  The litter from the experimental group had a total of 7 fetuses 
with no fetal resorptions.   
 
4.2.2: Weight and Length of Fetuses 
 Fetuses from the 0 ppb treatment group had an average weight of 0.89 
grams and an average crown-to-rump length of 19.63 centimeters.  Overall, 
fetuses from the 100 ppb treatment group had lower body measurements, 
with an average weight of 0.77 grams and an average crown-to-rump length 
of 17.36 centimeters (Table 10).  The difference in fetal weight was significant 
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between the two treatment groups (P=0.05, 95% confidence interval=-0.23 to 
0.00); however, the difference in fetal length was not (P=0.26, 95% confidence 
interval=-6.55 to 2.01).  Because the fetuses were not to term, sex could not 
be visually determined; future work will be directed towards identifying the 
sex of the fetuses to stratify the weight and crown-to-rump length data.   
 
4.2.3: Fetal Tissue Weight 
 The average placenta weight was higher for the 100 ppb group; the 
average weight of the fetal tissue was 0.082 grams for the control group and 
0.084 grams for the experimental group.  On the contrary, the 100 ppb 
treatment group had lower average lung and heart weights compared to the 0 
ppb treatment group.  The average weight of the lungs was 0.0318 grams for 
the control group and 0.0254 grams for the experimental group, while the 
average heart weight was 0.0047 grams for the control group and 0.0038 
grams for the experimental group (Table 10).  Overall the difference in 
placenta, lung, and heart tissue weight between the two groups was not 
significant (P=0.85, 95% confidence interval=-0.02 to 0.02, P=0.20, 95% 
confidence interval=-0.02 to 0.00, and P=0.18, 95% confidence interval=-0.01 




Table 10: Gestation day 17 euthanasia measurements.  N=3-7 fetuses from 1 













0 ppb 0.89 19.63 0.082 0.0318 0.0047 
100 ppb 0.77* 17.36 0.084 0.0254 0.0038 
 
4.3: Pre-Challenge Influenza A Virus Vaccine Immunogenicity 
4.3.1: Anti-Influenza A Virus Immunoglobulin G Titers 
 Immunoglobulin G is the most abundant antibody in circulation and 
tissue.  IgG mediates protection against local and systemic antigens by 
neutralizing, opsonizing, and eliminating pathogens such as viruses and 
bacteria (Vidarsson, Dekkers, and Rispens 2014).  Vaccines provide 
protection by inducing the production of antigen-specific IgG antibodies that 
can go into action upon reintroduction of the pathogen (Wang, Bournazos, 
and Ravetch 2018).   
Before challenge with the drift variant ma2009 H1N1 IAV, arsenic-
exposed female offspring from the 1st wave of mating had significantly higher 
total anti-ma2009 IAV IgG titers compared to arsenic-exposed male offspring 
(P=0.04, 95% confidence interval=-95.54 to -1.33).  In addition, even though 
100 ppb females had higher total anti-ma2009 IAV IgG titers compared to 0 
ppb females, the difference was not statistically significant (P=0.11, 95% 
confidence interval=-101.50 to 6.90); the difference in total anti-ma2009 IAV 
IgG titers between male offspring from the control group and male offspring 
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from the experimental group was also not significant (Figure 4; P=0.97, 95% 
confidence interval=-50.16 to 36.40 respectively).  When graphed by litter 
average, there were no significant differences in anti-ma2009 IAV IgG titers 
between treatment groups or sexes (Supplemental Figure 1).   
 
 
Figure 4: Pre-challenge (21 days post vaccination 2) anti-ma2009 IAV IgG 
titers for the 1st wave of mating.  N=7-14 offspring from 3 litters; statistical 
significance indicated by *P < 0.05.  
 
 From the 2nd wave of mating, female offspring from the 0 ppb 
treatment group had higher total anti-ma2009 IAV IgG titers compared to 
male offspring from the 0 ppb treatment group; however, this difference was 
 50 
not significant (P=0.07, 95% confidence interval=-40.78 to 1.25).  The 
difference in anti-ma2009 IAV IgG titers between 0 ppb males and 100 ppb 
males, as well as between 0 ppb females and 100 ppb females was also not 
significant (Figure 5; P=0.96, 95% confidence interval=-23.22 to 15.98 and 
P=0.94, 95% confidence interval=-19.07 to 29.74 respectively).  Furthermore, 
there were no significant differences in anti-ma2009 IAV IgG titers between 
treatment groups or sexes when graphed by litter average (Supplemental 
Figure 2).   
 
 
Figure 5: Pre-challenge (21 days post vaccination 2) anti-ma2009 IAV IgG 
titers for the 2nd wave of mating.  N=9-17 offspring from 4 to 5 litters; P < 
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4.3.2: Anti-Influenza A Virus Immunoglobulin G1 to G2a/c Titers 
 There are four subclasses of IgG.  Human IgG1, which is equivalent to 
mouse IgG2a, is the most abundant IgG subclass; in the C57BL/6 mouse 
strain, IgG2a is indistinguishable from IgG2c and are referred to in parallel 
(Zhang, Goldschmidt, and Salter 2012; Dekkers et al. 2017).  Human IgG1 
and mouse IgG2a/c play an important role in providing protection against 
protein antigens such as viruses.  Human IgG4, which is equivalent to mouse 
IgG1, is one of the less abundant IgG subclasses, but plays a key role in 
neutralizing polysaccharide antigens associated with bacterial infections 
(Vidarsson, Dekkers, and Rispens 2014).  In this setting, a smaller IgG1 to 
IgG2a/c ratio indicates greater protection from the vaccine.   
 For vaccinated offspring from the 1st wave of mating, females from the 
control group had significantly higher IgG1 to IgG2a/c titer ratios compared 
to males from the control group (P=0.01, 95% confidence interval=-1.35 to -
0.13).  However, there was no significance difference in IgG1 to IgG2a/c titer 
ratios when comparing between the two treatment groups for both male and 
female offspring (Figure 6; P=0.99, 95% confidence interval=-0.53 to 0.51 and 
P=0.65, 95% confidence interval=-0.37 to 0.93 respectively).  When graphed 
by litter average, there were no statistically significant differences in anti-
ma2009 IAV IgG1 to IgG2a/c titer ratios between treatment groups or sexes 
(Supplemental Figure 3).   
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Figure 6: Pre-challenge (21 days post vaccination 2) anti-ma2009 IAV IgG1 to 
IgG2a/c titer ratios for the 1st wave of mating.  N=7-14 offspring from 3 
litters; statistical significance indicated by *P < 0.05.  
 
 For vaccinated offspring from the 2nd wave of mating, there was no 
statistical significance in IgG1 to IgG2a/c titer ratios between the four 
different groups.  Additionally, the IgG1 to IgG2a/c titer ratios did not differ 
when comparing between the two treatment groups for either male or female 
offspring (Figure 7; P=0.59, 95% confidence interval=-0.69 to 0.25 and 
P=0.99, 95% confidence interval=-0.58 to 0.58 respectively).  There were no 
significant differences in anti-ma2009 IAV IgG1 to IgG2a/c titer ratios 
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between either treatment groups or sexes when graphed by litter average 
(Supplemental Figure 4).   
 
 
Figure 7: Pre-challenge (21 days post vaccination 2) anti-ma2009 IAV IgG1 to 
IgG2a/c titer ratios for the 2nd wave of mating.  N=9-17 offspring from 4 to 5 
litters; no significance.  
 
4.3.3: Antibody Neutralization Capacity 
 From the 1st wave of mating, female offspring from the 100 ppb group 
had significantly higher neutralizing antibody titers against the drift variant 
ma2009 H1N1 IAV compared to both 100 ppb male offspring and 0 ppb 
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P=0.01, 95% confidence interval=-9458 to -1105 respectively).  Arsenic did not 
have an effect on antibody neutralization capacity for male offspring (Figure 
8; P=0.99, 95% confidence interval=-3123 to 3545).  If graphed by litter 
average, the statistically significant difference in neutralizing antibody titers 
between treatment groups or sexes recedes (Supplemental Figure 13).   
 
 
Figure 8: Pre-challenge (21 days post vaccination 2) anti-DV ma2009 IAV 
neutralizing antibody titers for the 1st wave of mating.  N=7-14 offspring from 
3 litters; statistical significance indicated by *P < 0.05 and **P < 0.01.  
 
 From the 2nd wave of mating, there was no statistically significant 
difference in neutralizing antibody titers against the drift variant ma2009 
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H1N1 IAV between the four different groups.  In addition, there was no 
difference in neutralizing antibody titers between treatment groups for both 
male and female offspring (Figure 9; P=0.52, 95% confidence interval=-1359 
to 4236 and P=0.98, 95% confidence interval=-2908 to 3964 respectively).  
When graphed by litter average, there were no significant differences in 
neutralizing antibody titers between treatment groups or sexes 
(Supplemental Figure 14).   
 
 
Figure 9: Pre-challenge (21 days post vaccination 2) anti-DV ma2009 IAV 
neutralizing antibody titers for the 2nd wave of mating.  N=9-17 offspring 
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4.4: Phenotypic Measurements Following Challenge 
4.4.1: Body Weight Change 
 Following challenge with the drift variant ma2009 H1N1 IAV, 0 ppb 
male offspring from the 1st wave of mating had the greatest percent change in 
body weight compared to all other offspring groups (Figure 10).  Furthermore, 
male offspring from the 0 ppb treatment group had a significantly greater 
weight gain progression following challenge compared to male offspring from 
the 100 ppb treatment group (Figure 11; P=0.001).  In addition, 0 ppb females 
had a greater weight gain progression following challenge compared to 100 
ppb females, although this difference was not statistically significant (Figure 
12; P=0.09).  When graphed by litter average, the statistical significance 
between treatment groups was sustained (Supplemental Figures 15, 16, and 







Figure 10: Percent body weight change days post challenge (DPC) for 
offspring from the 1st wave of mating.  N=5-12 offspring from 3 litters; P < 
0.10 indicated by † and statistical significance indicated by ***P < 0.001.  
 
 
Figure 11: Percent body weight change days post challenge (DPC) for male 
offspring from the 1st wave of mating.  N=10-12 offspring from 3 litters; 




Figure 12: Percent body weight change days post challenge (DPC) for female 
offspring from the 1st wave of mating.  N=5-8 offspring from 3 litters; P < 0.10 
indicated by †.  
 
 From the 2nd wave of mating, female offspring from the experimental 
treatment group had the greatest loss in weight following challenge (Figure 
13).  Overall, both male and female offspring from the 0 ppb treatment group 
differed significantly in body weight change following challenge compared to 
the 100 ppb treatment group, with vaccinated offspring from the control 
group experiencing less weight loss after challenge with the drift variant 
ma2009 H1N1 IAV (Figure 14 and 15; P=0.002 and P=0.02 respectively).  
When graphed by litter average, differences in weight change following 
challenge remained statistically significant between the 0 ppb females and 



























Figure 13: Percent body weight change days post challenge (DPC) for 
offspring from the 2nd wave of mating.  N=9-17 offspring from 4 to 5 litters; 
statistical significance indicated by *P < 0.05 and **P < 0.01.  
 
 
Figure 14: Percent body weight change days post challenge (DPC) for male 
offspring from the 2nd wave of mating.  N=14-17 offspring from 4 to 5 litters; 




Figure 15: Percent body weight change days post challenge (DPC) for female 
offspring from the 2nd wave of mating.  N=9-11 offspring from 4 to 5 litters; 
statistical significance indicated by *P < 0.05. 
 
4.4.2: Temperature Change 
 Following challenge with the drift variant ma2009 H1N1 IAV, 
vaccinated offspring from the 1st wave of mating did not experience 
significant changes in temperature (Figure 16).  For both male and female 
offspring, in utero arsenic exposure did not have an effect on temperature 
change after challenge (Figure 17 and 18; P=0.89 and P=0.32 respectively).  
When graphed by litter average, there was no significant difference in 
temperature change following challenge between treatment groups 




Figure 16: Percent temperature change days post challenge (DPC) for 




Figure 17: Percent temperature change days post challenge (DPC) for male 


















































Figure 18: Percent temperature change days post challenge (DPC) for female 
offspring from the 1st wave of mating.  N=5-8 offspring from 3 litters; no 
significance.  
 
 For vaccinated offspring from the 2nd wave of mating, males and 
females from both the control and experimental groups did not experience 
critical changes in temperature following challenge (Figure 19).  The 
difference in temperature between 0 ppb males and 100 ppb males was not 
significant; however, the drop in temperature for 100 ppb females was 
statistically significant when compared to 0 ppb females (Figure 20 and 21; 
P=0.31 and P=0.001 respectively).  When graphed by litter average, the 
difference in temperature change following challenge remained statistically 
significant between the 0 ppb females and the 100 ppb females 


























Figure 19: Percent temperature change days post challenge (DPC) for 
offspring from the 2nd wave of mating.  N=9-17 offspring from 4 to 5 litters; 
statistical significance indicated by ***P < 0.001.  
 
 
Figure 20: Percent temperature change days post challenge (DPC) for male 

























Figure 21: Percent temperature change days post challenge (DPC) for female 
offspring from the 2nd wave of mating.  N=9-11 offspring from 4 to 5 litters; 
statistical significance indicated by ***P < 0.001.  
 
4.4.3: Presentation of Clinical Signs 
 Following challenge with the drift variant ma2009 H1N1 IAV, 
morbidity was measured through the presence of clinical signs including 
piloerection, hunched posture, lack of an escape response, and dyspnea (Foltz 
and Ullman-Cullere 1999; Burkholder et al. 2012).  Clinical signs were not 
observed for any of the vaccinated offspring from either the 1st or 2nd waves of 
mating.   
  
 65 
PART 5: DISCUSSION 
 
5.1: In Utero Arsenic Exposure and Birth Outcomes 
 In our experimental model, in utero exposure to arsenic did not result 
in significant changes to reproductive success, fetal resorptions, gestation 
length, or litter size compared to the control group (Table 6).  These results 
coincide with a similar study that used C57BL/6 mice and found no difference 
in reproductive success, gestation length, or litter size following in utero 
exposure to arsenic at a concentration of 10 ppb (Kozul-Horvath et al. 2012).  
Our findings also match another study that acutely exposed LM/Bc/Fnn dams 
to high doses of arsenic (4.8-14.4 mg/kg) between gestation day 7 and 8, 
which resulted in no difference in both fetal resorptions and litter size (Hill, 
Wlodarczyk, and Finnell 2008).   
 Looking at pooled data from the 1st and 2nd waves of mating, in utero 
arsenic exposure resulted in a significant decrease in crown-to-rump length 
for male pups; weight of male pups, as well as weight and crown-to-rump 
length of female pups were also lower for the arsenic-exposed group but the 
difference was not statistically significant (Table 9).  Our results concur with 
other in vivo studies looking at the effects of either chronic or acute in utero 
exposure to arsenic (Hood and Bishop 1972; Kozul-Horvath et al. 2012; Hill, 
Wlodarczyk, and Finnell 2008).   
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 The results from our study, as well as similar in vivo studies looking at 
the effect of in utero arsenic exposure on birth outcomes does not correspond 
to findings from epidemiology studies looking at human populations exposed 
to arsenic.  Studies conducted in Bangladesh have associated maternal and in 
utero arsenic exposure, at varying concentrations, with higher rates of 
spontaneous abortion and stillbirth, in addition to increased risk of preterm 
birth and low birth weight (Ahmad et al. 2001; Milton et al. 2005; Huyck et 
al. 2007).  These same findings on the adverse effects of arsenic on birth 
outcomes and newborn health were also found in the United States, Taiwan, 
and Mongolia (Gilbert-Diamond et al. 2016; Yang et al. 2003; Myers et al. 
2009).   
 In utero exposure to arsenic resulted in a significant decrease in fetal 
weight on gestation day 17, but no difference in placenta weight; this novel 
finding supports both in vivo and epidemiology studies that link arsenic to 
low birth weight (Table 10; Kozul-Harvath et al. 2012; Huyck et al. 2007).  
Although we did not find significant differences in heart or lung tissue weight 
at gestation day 17, other studies have linked in utero arsenic exposure to 
lower weight of male reproductive organs including the testes, seminal 
vesicle, and prostate (Table 10; Reddy et al. 2012).   
The adverse reproductive effects of in utero arsenic exposure could be 
linked to the metalloid’s ability to cause inflammation and oxidative stress.  
Results from a population-based study in Bangladesh indicated that in utero 
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arsenic exposure increased markers of oxidative damage in the placenta, as 
well as increased pro-inflammatory cytokines, including interleukin 1 beta 
and tumor necrosis factor alpha, in both placental tissue and cord blood 
(Ahmed et al. 2011).  Supporting animal studies have investigated arsenic as 
a reproductive toxin and found that exposure to the metalloid during 
pregnancy increased fibrosis, hemorrhagic regions, and infarct lesions in the 
placenta.  This same study observed a decrease in expression of glucose 
transporter type 4, which is an insulin-regulated transporter that plays an 
important role in maintaining the metabolic needs of the placenta during the 
early stages of pregnancy; this decrease in glucose transporter expression 
could be linked to fetal nutrition, and ultimately fetal weight and health 
(Gutierrez-Torres et al. 2015; Ericsson et al. 2005).  Another animal study 
discovered that the metalloid increases maternal metallothionein levels in 
the liver, resulting in decreased zinc accumulation in the fetus; deficient 
levels of zinc during development is linked to embryotoxicity and can even 
lead to fetal death (Taubeneck et al. 1994; Golub, Macintosh, and Baumrind 
1998).   
 Both animal and human studies have confirmed that arsenic readily 
crosses the placenta to reach the developing fetus.  Concentrations of arsenic 
metabolites, including MMA and DMA, found in placental tissue significantly 
correlate with metabolites found in both cord blood and urine, as well as fetal 
organs such as the liver and brain (Hood et al. 1988; Jin et al. 2006; Concha 
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et al. 1998; Markowski et al. 2010).  In addition, in utero arsenic exposure 
has been shown to alter lung size and mechanics, as well as up-regulate 
genes involved in mucus production and innate immunity (Ramsey et al. 
2013c).  Furthermore, in utero and postnatal exposure to arsenic has been 
linked to declines in infant health, measured through increased rates of 
bronchiectasis and respiratory tract infections (Smith et al. 2006; Farzan et 
al. 2013).   
 
5.2: Effect of In Utero Arsenic on Influenza Vaccine Efficacy 
 Overall, results from our study indicate that in utero arsenic exposure 
does not adversely alter influenza vaccine efficacy in the offspring, evaluated 
through antibody titers, as well as body weight and temperature change 
following intranasal challenge.  Looking at pre-challenge anti-ma2009 IAV 
IgG titers, arsenic-exposed offspring did not have lower titers compared to 
controls, demonstrating that arsenic, at a concentration of 100 ppb, does not 
change vaccine immunogenicity.  Additionally, female offspring from both 
treatment groups appear to produce more anti-ma2009 IAV IgG compared to 
their male counterparts (Figures 4 and 5).  There was also no difference in 
IgG1 to IgG2a/c titer ratios between the two treatment groups (Figures 6 and 
7).  Looking at neutralizing antibody titers from the 1st wave of mating, 
female offspring from the 100 ppb treatment group had significantly greater 
neutralizing capacity compared to female offspring from the 0 ppb treatment 
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group (Figures 8 and 9); the 1st wave of mating was immunized with 17.99 
μg/dose for the first vaccination and 32.16 μg/dose for the second vaccination, 
while the 2nd wave of mating was immunized with 33.22 μg/dose for the first 
vaccination and 36.19 μg/dose for the second vaccination (Table 1).   
 By comparing pre-challenge immunogenicity endpoints including total 
anti-ma2009 IAV IgG titers, IgG1 to IgG2a/c titer ratios, and neutralizing 
antibody titers between the 1st and 2nd waves of mating, the results do not 
support the idea that vaccinating with a higher concentration of inactivated 
viral protein results in a greater antibody-mediated immune response.  
Generally, offspring from the 1st wave of mating initiated a more protective 
response following vaccination compared to offspring from the 2nd wave of 
mating, although not statistically significant.   
 Since arsenic is a known immunotoxin, it was hypothesized that in 
utero exposure to the metalloid would decrease influenza vaccine efficacy in 
the offspring (as reviewed by Dangleben, Skibola, and Smith 2013; World 
Health Organization 2018).  In addition, because B cells of neonates and 
infant are undergoing development and have lower expression of T cell and 
complement receptors, as well as decreased somatic hypermutation when 
compared to adults, it results in a dampened humoral immune response and 
blunted affinity maturation of antibodies (as reviewed by Simon, Hollander, 
and McMichael 2015; Glaesener et al. 2018).  In our study, we did not observe 
a diminished immune response following vaccination in both male and female 
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offspring exposed to arsenic in utero.  This could possibly be due to the fact 
that the offspring were vaccinated during the juvenile life stage rather than 
during infancy, resulting in a more robust antibody-mediate immune 
response following vaccination.  Although still undergoing development 
during childhood, the immune system shifts away from a strong Th2 response 
that is characteristic of development and infancy to favor a Th1 response 
upon antigen presentation (as reviewed by Simon, Hollander, and McMichael 
2015; Hannet et al. 1992; Spellberg and Edwards 2001).   
 A previous epidemiology study has shown that exposure to arsenic 
does not adversely alter the immunogenicity of the inactivated cholera 
vaccine or the tetanus and diphtheria toxoid vaccines; this same study also 
found that arsenic did not effect the immunogenicity of the live-attenuated 
measles vaccine (Saha et al. 2013; Clem 2011; Centers for Disease Control 
and Prevention 2013).  However, another epidemiology study has shown that 
early life exposure to arsenic can decrease the levels of mumps-specific IgG 
following immunization with the live-attenuated vaccine (Raqib et al. 2017).  
In our study, offspring exposed to arsenic in utero were vaccinated with an 
inactivated IAV vaccine.  Pre-challenge titers showed no significant 
difference in immunogenicity between the arsenic-exposed offspring and the 
control offspring.  Because of the results from Raqib et al., it suggests that 
the immunogenicity of live-attenuated vaccines may be more susceptible to 
the immunotoxic effects of arsenic.  Using a live-attenuated IAV vaccine, 
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currently under development by Drs. Sabra Klein and Andrew Pekosz (Johns 
Hopkins Bloomberg School of Public Health), could yield different results that 
support arsenic’s ability to adversely alter vaccine immunogenicity.   
 Overall, pre-challenge measurements of antibody quantity and 
functionality do not support the established concept that females mount a 
greater antibody-mediated immune response following vaccination.  Both 
animal and human studies have demonstrated that biological sex plays a 
critical role in influenza vaccine efficacy.  Although age and physiological 
factors including genetics and microbiome composition play a significant role, 
females tend to initiate higher antibody responses following immunization 
with the influenza vaccine (Klein and Pekosz 2014; Klein, Marriot, and Fish 
2015).  This is likely because of testosterone’s immunosuppressive property, 
resulting in males having lower CD4 to CD8 ratios, producing decreased Th2 
cytokine responses, and having lower levels of antigen-specific 
immunoglobulins following vaccination when compared to females (Furman 
et al. 2014; Klein, Marriot, and Fish 2015; Lorenzo et al. 2011).  Our findings 
show that female offspring do not mount significantly greater antibody-
mediated immune responses following vaccination when compared to male 
offspring.  This is likely because the offspring were not sexually mature when 
they were vaccinated at 2 and 5 weeks of age, and therefore sex hormones 
like estrogen and testosterone did not play a key role in modulating the 
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immune response (Fink and Klein 2018; Jackson et al. 2017; The Jackson 
Laboratory 2016).   
 Because this was the first study to investigate how in utero arsenic 
exposure alters influenza vaccine efficacy in the offspring, one of our primary 
objectives was to test different vaccine concentrations to establish what dose 
is the most optimal, as well as to determine whether a higher concentration 
of vaccine elicited a greater antibody-mediated response.  Typically, adults 
are vaccinated with 15 μg/dose of inactivated viral protein every influenza 
season, while naïve children between the age of 6 months to 8 years who have 
never received an influenza vaccine are immunized with 2 doses of vaccine at 
a concentration of 15 μg/dose (Centers for Disease Control and Prevention 
2019b; Centers for Disease Control and Prevention 2017).  In the adult 
ma2009 H1N1 IAV vaccine model established by Drs. Sabra Klein and 
Andrew Pekosz (Johns Hopkins Bloomberg School of Public Health), mice 
receive 2 doses of inactivated viral protein at a concentration of 20 μg/dose 
(Fink et al. 2018).  Although the 2nd wave of mating was vaccinated with a 
higher concentration of inactivated viral protein, the offspring did not mount 
a greater response.  This may possibly be due to a plateaued immune 
response following vaccination with a redundant amount of viral protein 
(Slifka and Amanna 2014).   
 Following challenge with the drift variant ma2009 H1N1 IAV, male 
and female offspring from both treatment groups did not experience a 
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significant drop in either weight or temperature, demonstrating the efficacy 
of the IAV vaccine (Figures 10, 13, 16, and 19).  In addition, 0 ppb male 
offspring gained the greatest percentage of weight following challenge, 
followed by 100 ppb males, 0 ppb females, and 100 ppb females respectively 
(Figures 10 and 13).  These findings correspond to various animal and human 
studies that have linked arsenic exposure with lower body weight compared 
to control groups (Kozul-Horvath et al. 2012; Hopenhayn et al. 2003; Nermell 
et al. 2008).  Being underweight has been shown to be an important risk 
factor for both complications and hospitalizations associated with respiratory 
infections including influenza (Karki et al. 2018; Okubo et al. 2018; Moser et 
al. 2019).   
 Previous studies have established that arsenic is a developmental 
toxin, and that in utero exposure negatively affects lung development.  In 
utero arsenic exposure not only causes a decrease in lung weight, but also 
reduces thoracic gas volume and increased lung tissue elastance (Ramsey et 
al. 2013b; Ramsey et al. 2013c; Petrick et al. 2009).  Although we did observe 
signs of malaise in our study, altered lung structure and mechanics could 
lead to greater susceptibility to respiratory diseases, as well as higher 
morbidity and mortality (Ramsey et al. 2013c; Lantz et al. 2009).   
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PART 6: CONCLUSION 
 
6.1: Key Findings 
 Arsenic is a common groundwater contaminant and millions of 
individuals consume drinking water with arsenic concentrations that far 
exceed the World Health Organization standard of 10 μg/L or ppb.  Arsenic is 
a known carcinogen, immunotoxin, and endocrine disruptor, as well as a 
reproductive and developmental toxin (World Health Organization 2018).   
 Our findings show that in utero exposure to the metalloid, at a 
concentration of 100 ppb, has negative effects on both fetal and pup weight.  
Although we did not observe any differences in antibody-mediated immune 
responses following vaccination, nuanced differences may have been seen at 
lower vaccination concentrations that more accurately model the human 
vaccination schedule.  Another important finding from the study is that in 
utero arsenic exposure results in lower body weight during adulthood, which 
could contribute to greater morbidity and mortality to respiratory infections 
like the influenza virus (Karki et al. 2018; Okubo et al. 2018; Moser et al. 
2019).   
 
6.2: Public Health Impact 
 This study was the first to look at the effects of in utero arsenic 
exposure on juvenile IAV vaccine immunogenicity and subsequent infection 
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susceptibility during adulthood.  The results from this study indicate that 
exposure to the metalloid throughout pregnancy does not negatively alter the 
efficacy of the inactivated influenza vaccine in the offspring.  These findings 
are promising for public health since they suggest that individuals exposed to 
arsenic in utero can be well-protected from influenza-related morbidity and 
mortality by vaccination with an inactivated IAV vaccine.   
 
6.3: Future Directions 
 Preliminary data collected from the gestation day 17 euthanasia show 
a trend, albeit not significant, between in utero arsenic exposure and 
decreased fetal weight and crown-to-rump length, as well as a reduction in 
weight of fetal organs including the lungs and heart.  Future efforts should be 
directed towards replicating this experimental design to strengthen this 
association.  In addition, arsenic speciation should be compared between 
maternal tissue and fetal tissue to quantify how much arsenic and what 
metabolites are transferred from mother to fetus.  Focusing on the placenta, 
gene and protein expression should also be investigated to look at changes in 
activity of key nutrient transporters including the sodium-coupled neutral 
amino acid transporter and the fatty acid transport protein which provide 
channels for the movement of nutrients from mother to fetus (Brett et al. 
2014; Desforges et al. 2010).   
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 Another future direction of this project is to alter the vaccine 
concentrations used to immunize the offspring.  The results showing 
immunogenicity of the vaccine demonstrate a plateau effect for the 2nd wave 
of mating since the offspring overall produced a lower antibody-mediated 
response compared to the 1st wave of mating.  By using a lower vaccine 
concentration, subtle differences in anti-ma2009 IAV IgG titers or 
neutralizing antibody titers, modulated by in utero arsenic exposure, may 
become more evident.  In addition, instead of using inactivated viral protein 
for intraperitoneal immunization, the offspring could be intransally 
vaccinated with a live-attenuated vaccine that is currently under 
development.  Live-attenuated vaccines elicit a different immune response 
compared to inactivated vaccines; live-attenuated vaccines are characterized 
by high IgA and IgM levels in the mucosal tissues of the respiratory tract 
following immunization whereas inactivated vaccines are primarily 
correlated with high levels of serum IgG (Cox, Brokstad, and Ogra 2004; 
Chung et al. 2019).  Because of the difference in immune response, the live-
attenuated vaccine may be more sensitive to the immunotoxic effects 
associated with arsenic exposure.   
 Previous work looking at the effects of chronic arsenic exposure and 
influenza vaccine efficacy conducted by Sarah Attreed, a current doctoral 
student, has shown that the metalloid significantly increases pro-
inflammatory cytokines and chemokines including interleukin 9, interleukin 
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18, and monocyte chemoattractant protein 1 following both vaccination and 
intranasal challenge.  Pro-inflammatory cytokines increase disease severity, 
and play an important role in response to infection and tissue damage (Van 
Reeth 2000; Sladkova and Kostolansky 2006; Betakova et al. 2017; Dinarello 
2000).  Because of these previous findings in an adult mouse model, future 
work should be directed towards looking at pro-inflammatory cytokines and 
chemokines in lung homogenates of vaccinated offspring exposed to arsenic in 
utero.   
 In addition to looking at pro-inflammatory cytokines, lung 
homogenates can also be used to look at viral titers.  Previous work by Sarah 
Attreed, as well as work by Kozul et al. and Ramsey et al. has shown 
increased viral load for unvaccinated adult mice chronically exposed to 
arsenic; higher viral titers indicate greater viral replication and are 
correlated with more severe symptoms (Kozul et al. 2009; Ramsey et al. 
2013a; Koopman et al. 2016; Chen et al. 2012; ).  Although phenotypic 
measurements including body weight and temperature did not indicate 
significant morbidity following intranasal challenge, it would be beneficial to 
measure viral titers in lung homogenates to look for differences in viral 
replication and clearance between the experimental and control offspring 
(Lee et al. 2009; Baccam et al. 2006).   
 Following challenge with the drift variant ma2009 H1N1 IAV, tissues 
including lungs, spleen, thymus, and mediastinal lymph nodes were collected 
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and cryopreserved for future work.  Another important direction is to look at 
these tissue samples using flow cytometry to see if there are differences in 
immune cell populations between exposed and unexposed offspring; 
important cell populations to quantify include antigen-specific T cells, as well 
as memory B cells (Henry et al. 2019; Powell et al. 2013; Schulze-Horsel, 
Genzel, and Reichl 2008).  In addition, important markers of influenza 
infection including viral nucleoprotein and matrix protein 1 could be 
investigated using gene and protein expression (Schulze-Horsel, Genzel, and 
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Supplemental Figure 1: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG titers for the 1st wave of mating, graphed by litter average.  
Male and female offspring were immunized with 17.99 μg/dose for vaccination 
1 at 2 weeks of age, and 33.22 μg/dose for vaccination 2 at 5 weeks of age.  




Supplemental Figure 2: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG titers for the 2nd wave of mating, graphed by litter average.  
Male and female offspring were immunized with 32.16 μg/dose for vaccination 
1 at 2 weeks of age, and 36.19 μg/dose for vaccination 2 at 5 weeks of age.  
N=4-5 litters with the number of pups per data point ranging from 1 to 6; no 
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Supplemental Figure 3: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1:IgG2a/c titer ratios for the 1st wave of mating, graphed by 
litter average.  Male and female offspring were immunized with 17.99 μg/dose 
for vaccination 1 at 2 weeks of age, and 33.22 μg/dose for vaccination 2 at 5 
weeks of age.  N=3 litters, with the number of pups per data point ranging 
from 1 to 8; P < 0.10 indicated by †.  
 
 
Supplemental Figure 4: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1:IgG2a/c titer ratios for the 2nd wave of mating, graphed by 
litter average.  Male and female offspring were immunized with 32.16 μg/dose 
for vaccination 1 at 2 weeks of age, and 36.19 μg/dose for vaccination 2 at 5 
weeks of age.  N=4-5 litters with the number of pups per data point ranging 
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Supplemental Figure 5: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1 titers for the 1st wave of mating.  Male and female 
offspring were immunized with 17.99 μg/dose for vaccination 1 at 2 weeks of 
age, and 33.22 μg/dose for vaccination 2 at 5 weeks of age.  N=7-14 offspring 
from 3 litters; statistical significance indicated by *P < 0.05.   
 
 
Supplemental Figure 6: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1 titers for the 1st wave of mating, graphed by litter average.  
Male and female offspring were immunized with 17.99 μg/dose for vaccination 
1 at 2 weeks of age, and 33.22 μg/dose for vaccination 2 at 5 weeks of age.  
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Supplemental Figure 7: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1 titers for the 2nd wave of mating.  Male and female 
offspring were immunized with 32.16 μg/dose for vaccination 1 at 2 weeks of 
age, and 36.19 μg/dose for vaccination 2 at 5 weeks of age.  N=9-17 offspring 
from 4 to 5 litters; P < 0.10 indicated by †. 
 
 
Supplemental Figure 8: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG1 titers for the 2nd wave of mating, graphed by litter average.  
Male and female offspring were immunized with 32.16 μg/dose for vaccination 
1 at 2 weeks of age, and 36.19 μg/dose for vaccination 2 at 5 weeks of age.  
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Supplemental Figure 9: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG2a/c titers for the 1st wave of mating.  Male and female 
offspring were immunized with 17.99 μg/dose for vaccination 1 at 2 weeks of 
age, and 33.22 μg/dose for vaccination 2 at 5 weeks of age.  N=7-14 offspring 
from 3 litters; no significance.   
 
 
Supplemental Figure 10: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG2a/c titers for the 1st wave of mating, graphed by litter 
average.  Male and female offspring were immunized with 17.99 μg/dose for 
vaccination 1 at 2 weeks of age, and 33.22 μg/dose for vaccination 2 at 5 
weeks of age.  N=3 litters, with the number of pups per data point ranging 





























































































































Supplemental Figure 11: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG2a/c titers for the 2nd wave of mating.  Male and female 
offspring were immunized with 32.16 μg/dose for vaccination 1 at 2 weeks of 
age, and 36.19 μg/dose for vaccination 2 at 5 weeks of age.  N=9-17 offspring 
from 4 to 5 litters; no significance.   
 
 
Supplemental Figure 12: Pre-challenge (21 days post vaccination 2) anti-
ma2009 IAV IgG2a/c titers for the 2nd wave of mating, graphed by litter 
average.  Male and female offspring were immunized with 32.16 μg/dose for 
vaccination 1 at 2 weeks of age, and 36.19 μg/dose for vaccination 2 at 5 
weeks of age.  N=4-5 litters with the number of pups per data point ranging 
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Supplemental Figure 13: Pre-challenge (21 days post vaccination 2) anti-DV 
ma2009 IAV neutralizing antibody titers for the 1st wave of mating, graphed 
by litter average.  Male and female offspring were immunized with 17.99 
μg/dose for vaccination 1 at 2 weeks of age, and 33.22 μg/dose for vaccination 
2 at 5 weeks of age.  N=3 litters, with the number of pups per data point 
ranging from 1 to 8; no significance.   
 
 
Supplemental Figure 14: Pre-challenge (21 days post vaccination 2) anti-DV 
ma2009 IAV neutralizing antibody titers for the 2nd wave of mating, graphed 
by litter average.  Male and female offspring were immunized with 32.16 
μg/dose for vaccination 1 at 2 weeks of age, and 36.19 μg/dose for vaccination 
2 at 5 weeks of age.  N=4-5 litters with the number of pups per data point 
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Supplemental Figure 15: Percent body weight change days post challenge 
(DPC) for offspring from the 1st wave of mating, graphed by litter average.  At 
8 weeks of age, offspring were intranasally challenged with a lethal dose of 
105 tissue culture infectious dose of the drift variant ma2009 H1N1 IAV.  N=3 
litters, with the number of pups per data point ranging from 1 to 5; P < 0.10 




Supplemental Figure 16: Percent body weight change days post challenge 
(DPC) for male offspring from the 1st wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=3 litters, with the number of pups per data point ranging from 
2 to 5; statistical significance indicated by ***P < 0.001.  
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Supplemental Figure 17: Percent body weight change days post challenge 
(DPC) for female offspring from the 1st wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=3 litters, with the number of pups per data point ranging from 




Supplemental Figure 18: Percent body weight change days post challenge 
(DPC) for offspring from the 2nd wave of mating, graphed by litter average.  
At 8 weeks of age, offspring were intranasally challenged with a lethal dose of 
105 tissue culture infectious dose of the drift variant ma2009 H1N1 IAV.  
N=4-5 litters with the number of pups per data point ranging from 1 to 5; 




























Supplemental Figure 19: Percent body weight change days post challenge 
(DPC) for male offspring from the 2nd wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=4-5 litters with the number of pups per data point ranging 




Supplemental Figure 20: Percent body weight change days post challenge 
(DPC) for female offspring from the 2nd wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=4-5 litters with the number of pups per data point ranging 


























Supplemental Figure 21: Percent temperature change days post challenge 
(DPC) for offspring from the 1st wave of mating, graphed by litter average.  At 
8 weeks of age, offspring were intranasally challenged with a lethal dose of 
105 tissue culture infectious dose of the drift variant ma2009 H1N1 IAV.  N=3 
litters, with the number of pups per data point ranging from 1 to 5; no 
significance.   
 
 
Supplemental Figure 22: Percent temperature change days post challenge 
(DPC) for male offspring from the 1st wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=3 litters, with the number of pups per data point ranging from 

















































Supplemental Figure 23: Percent temperature change days post challenge 
(DPC) for female offspring from the 1st wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=3 litters, with the number of pups per data point ranging from 




Supplemental Figure 24: Percent temperature change days post challenge 
(DPC) for offspring from the 2nd wave of mating, graphed by litter average.  
At 8 weeks of age, offspring were intranasally challenged with a lethal dose of 
105 tissue culture infectious dose of the drift variant ma2009 H1N1 IAV.  
N=4-5 litters with the number of pups per data point ranging from 1 to 5; 

























Supplemental Figure 25: Percent temperature change days post challenge 
(DPC) for male offspring from the 2nd wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=4-5 litters with the number of pups per data point ranging 




Supplemental Figure 26: Percent temperature change days post challenge 
(DPC) for female offspring from the 2nd wave of mating, graphed by litter 
average.  At 8 weeks of age, offspring were intranasally challenged with a 
lethal dose of 105 tissue culture infectious dose of the drift variant ma2009 
H1N1 IAV.  N=4-5 litters with the number of pups per data point ranging 
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